clobetasol and Diabetes-Mellitus--Type-2

Topics: Acanthosis Nigricans; Administration, Cutaneous; Aged; Clobetasol; Diabetes Mellitus, Type 2; Glucocorticoids; Humans; Hypoglycemic Agents; Injection Site Reaction; Injections, Intralesional; Injections, Subcutaneous; Insulin; Male

Bullous pemfigoid (BP), an autoimmune disorder, can also be induced by some medications. Vildagliptin is a new drug used to treat diabetes mellitus (DM). Recently, a few cases of vildagliptin-induced BP have been described in the literature. We report a patient with BP in which vildagliptin was thought to be as a possible causative agent. The awareness of BP development risk during gliptin therapy can prevent unnecessary usage of systemic drugs with serious side effects.

Topics: Adamantane; Administration, Cutaneous; Clobetasol; Complement C3; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Eruptions; Female; Fluorescent Antibody Technique; Gliclazide; Glucocorticoids; Humans; Hypoglycemic Agents; Metformin; Middle Aged; Nitriles; Pemphigoid, Bullous; Pyrrolidines; Skin; Vildagliptin; Withholding Treatment

Oral hairy leukoplakia (OHL) presents as a white, plaque-like lesion typically occurring on the lateral border of the tongue. This condition is caused by the Epstein-Barr virus, a human herpesvirus that often establishes lifelong, asymptomatic latent infection. OHL, initially described in immunocompromised men infected with the human immunodeficiency virus (HIV), has also been described in other severely immunocompromised patients. Only rarely has OHL been reported in less profoundly immunocompromised patients primarily in the setting of corticosteroid therapy. Here we report on two additional cases of OHL attributable to immunosuppressive medications.

Topics: Aged; Anti-Infective Agents; Anti-Inflammatory Agents; Antifungal Agents; Arthritis, Rheumatoid; Clobetasol; Dapsone; Dermatologic Agents; Dexamethasone; Diabetes Mellitus, Type 2; Epstein-Barr Virus Infections; Female; Fluconazole; Humans; Immunocompromised Host; Leukoplakia, Hairy; Lichen Planus; Methotrexate; Nystatin; Prednisone; Zinc Oxide

We describe four patients with generalized bullous pemphigoid, who received treatment with oral prednisone and suffered serious corticosteroid-induced iatrogenesis. In all cases, we decided to quickly withdraw the systemic corticosteroid treatment and begin treatment with 0.05 % clobetasol propionate (20 g/day). New outbreaks of pemphigoid or significant side effects were not seen after this change in medication. The topical treatment went on for five to twelve months, and the patients were followed up for extended periods after treatment ended, with no recurrences being observed. Systemic corticosteroid treatment may be replaced by topical treatment without complications, and this may be especially indicated in patients with serious corticosteroid-induced iatrogenesis.

Topics: Administration, Cutaneous; Aged; Aged, 80 and over; Amputation, Surgical; Clobetasol; Comorbidity; Diabetes Mellitus, Type 2; Female; Humans; Hypertension; Iatrogenic Disease; Immunosuppressive Agents; Ischemia; Leg; Pemphigoid, Bullous; Pneumonia; Prednisone; Stroke

A 72-year-old man with diabetes-associated scleredema is presented. The patient had a long history of diabetes mellitus that had been difficult to control with complications of retinopathy, nephropathy, and arteriosclerosis leading to myocardial infarcts and stroke. The scleredema has remained stable with 4 months of topical clobetasol ointment twice daily and biweekly physical therapy. Diseases associated with scleredema and therapeutic options are summarized.

Topics: Aged; Anti-Inflammatory Agents; Clobetasol; Diabetes Mellitus, Type 2; Humans; Male; Physical Therapy Modalities; Scleredema Adultorum